Cargando…
Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management
Lung cancer is the leading cause of cancer-related deaths worldwide. Despite growing efforts for its early detection by screening populations at risk, the majority of lung cancer patients are still diagnosed in an advanced stage. The management of lung cancer has dramatically improved in the last de...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8624402/ https://www.ncbi.nlm.nih.gov/pubmed/34834454 http://dx.doi.org/10.3390/jpm11111102 |
_version_ | 1784606165661908992 |
---|---|
author | Šutić, Maja Vukić, Ana Baranašić, Jurica Försti, Asta Džubur, Feđa Samaržija, Miroslav Jakopović, Marko Brčić, Luka Knežević, Jelena |
author_facet | Šutić, Maja Vukić, Ana Baranašić, Jurica Försti, Asta Džubur, Feđa Samaržija, Miroslav Jakopović, Marko Brčić, Luka Knežević, Jelena |
author_sort | Šutić, Maja |
collection | PubMed |
description | Lung cancer is the leading cause of cancer-related deaths worldwide. Despite growing efforts for its early detection by screening populations at risk, the majority of lung cancer patients are still diagnosed in an advanced stage. The management of lung cancer has dramatically improved in the last decade and is no longer based on the “one-fits-all” paradigm or the general histological classification of non-small cell versus small cell lung cancer. Emerging options of targeted therapies and immunotherapies have shifted the management of lung cancer to a more personalized treatment approach, significantly influencing the clinical course and outcome of the disease. Molecular biomarkers have emerged as valuable tools in the prognosis and prediction of therapy response. In this review, we discuss the relevant biomarkers used in the clinical management of lung tumors, from diagnosis to prognosis. We also discuss promising new biomarkers, focusing on non-small cell lung cancer as the most abundant type of lung cancer. |
format | Online Article Text |
id | pubmed-8624402 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86244022021-11-27 Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management Šutić, Maja Vukić, Ana Baranašić, Jurica Försti, Asta Džubur, Feđa Samaržija, Miroslav Jakopović, Marko Brčić, Luka Knežević, Jelena J Pers Med Review Lung cancer is the leading cause of cancer-related deaths worldwide. Despite growing efforts for its early detection by screening populations at risk, the majority of lung cancer patients are still diagnosed in an advanced stage. The management of lung cancer has dramatically improved in the last decade and is no longer based on the “one-fits-all” paradigm or the general histological classification of non-small cell versus small cell lung cancer. Emerging options of targeted therapies and immunotherapies have shifted the management of lung cancer to a more personalized treatment approach, significantly influencing the clinical course and outcome of the disease. Molecular biomarkers have emerged as valuable tools in the prognosis and prediction of therapy response. In this review, we discuss the relevant biomarkers used in the clinical management of lung tumors, from diagnosis to prognosis. We also discuss promising new biomarkers, focusing on non-small cell lung cancer as the most abundant type of lung cancer. MDPI 2021-10-27 /pmc/articles/PMC8624402/ /pubmed/34834454 http://dx.doi.org/10.3390/jpm11111102 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Šutić, Maja Vukić, Ana Baranašić, Jurica Försti, Asta Džubur, Feđa Samaržija, Miroslav Jakopović, Marko Brčić, Luka Knežević, Jelena Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management |
title | Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management |
title_full | Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management |
title_fullStr | Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management |
title_full_unstemmed | Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management |
title_short | Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management |
title_sort | diagnostic, predictive, and prognostic biomarkers in non-small cell lung cancer (nsclc) management |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8624402/ https://www.ncbi.nlm.nih.gov/pubmed/34834454 http://dx.doi.org/10.3390/jpm11111102 |
work_keys_str_mv | AT suticmaja diagnosticpredictiveandprognosticbiomarkersinnonsmallcelllungcancernsclcmanagement AT vukicana diagnosticpredictiveandprognosticbiomarkersinnonsmallcelllungcancernsclcmanagement AT baranasicjurica diagnosticpredictiveandprognosticbiomarkersinnonsmallcelllungcancernsclcmanagement AT forstiasta diagnosticpredictiveandprognosticbiomarkersinnonsmallcelllungcancernsclcmanagement AT dzuburfeđa diagnosticpredictiveandprognosticbiomarkersinnonsmallcelllungcancernsclcmanagement AT samarzijamiroslav diagnosticpredictiveandprognosticbiomarkersinnonsmallcelllungcancernsclcmanagement AT jakopovicmarko diagnosticpredictiveandprognosticbiomarkersinnonsmallcelllungcancernsclcmanagement AT brcicluka diagnosticpredictiveandprognosticbiomarkersinnonsmallcelllungcancernsclcmanagement AT knezevicjelena diagnosticpredictiveandprognosticbiomarkersinnonsmallcelllungcancernsclcmanagement |